======= WARS =======


== Gene Information ==
  * **<color #00a2e8>Official Symbol</color>**: WARS1
  * **<color #00a2e8>Official Name</color>**: tryptophanyl-tRNA synthetase 1
  * **<color #00a2e8>Aliases and Previous Symbols</color>**: N/A
  * **<color #00a2e8>Entrez ID</color>**: [[https://www.ncbi.nlm.nih.gov/gene/?term=7453|7453]]
  * **<color #00a2e8>UniProt</color>**: [[https://www.uniprot.org/uniprot/P23381|P23381]]
  * **<color #00a2e8>Interactions</color>**: [[https://thebiogrid.org/search.php?search=WARS&organism=9606|BioGRID]]
  * **<color #00a2e8>PubMed articles</color>**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20WARS|Open PubMed]]
  * **<color #00a2e8>OMIM</color>**: [[https://omim.org/entry/191050|Open OMIM]]

== Function Summary ==
  * **<color #00a2e8>Entrez Summary</color>**: N/A
  * **<color #00a2e8>UniProt Summary</color>**:  Isoform 1, isoform 2 and T1-TrpRS have aminoacylation activity while T2-TrpRS lacks it. Isoform 2, T1-TrpRS and T2-TrpRS possess angiostatic activity whereas isoform 1 lacks it. T2-TrpRS inhibits fluid shear stress-activated responses of endothelial cells. Regulates ERK, Akt, and eNOS activation pathways that are associated with angiogenesis, cytoskeletal reorganization and shear stress-responsive gene expression. {ECO:0000269|PubMed:11773625, ECO:0000269|PubMed:11773626, ECO:0000269|PubMed:1373391, ECO:0000269|PubMed:14630953}.

<button type='primary' size='sm' modal='Pfam_Domains'>Pfam Domains</button>
<button type='primary' size='sm' modal='GO_terms'>GO Terms</button>


<modal id='Pfam_Domains' size='lg' title='Pfam Domains'>
|WHEP-TRS|
|tRNA-synt 1b|
</modal>

<modal id='GO_terms' size='lg' title='GO Terms'>
|tryptophan-tRNA ligase activity|
|tryptophanyl-tRNA aminoacylation|
|kinase inhibitor activity|
|regulation of protein ADP-ribosylation|
|tRNA aminoacylation for protein translation|
|tRNA aminoacylation|
|amino acid activation|
|tRNA metabolic process|
|negative regulation of protein kinase activity|
|protein domain specific binding|
|negative regulation of kinase activity|
|positive regulation of protein complex assembly|
|negative regulation of transferase activity|
|regulation of angiogenesis|
|cellular amino acid metabolic process|
|angiogenesis|
|regulation of vasculature development|
|translation|
|negative regulation of protein phosphorylation|
|peptide biosynthetic process|
|blood vessel morphogenesis|
|negative regulation of phosphorylation|
|regulation of protein complex assembly|
|protein kinase binding|
|ncRNA metabolic process|
|blood vessel development|
|vasculature development|
|cardiovascular system development|
|positive regulation of cellular component biogenesis|
|amide biosynthetic process|
|peptide metabolic process|
|negative regulation of phosphate metabolic process|
|negative regulation of phosphorus metabolic process|
|negative regulation of protein modification process|
|protein-containing complex|
|tube morphogenesis|
|negative regulation of cell population proliferation|
|cellular amide metabolic process|
|negative regulation of catalytic activity|
|regulation of protein kinase activity|
|tube development|
|circulatory system development|
|regulation of kinase activity|
|protein homodimerization activity|
|anatomical structure formation involved in morphogenesis|
|carboxylic acid metabolic process|
|regulation of cellular component biogenesis|
|regulation of transferase activity|
|oxoacid metabolic process|
|organic acid metabolic process|
|negative regulation of cellular protein metabolic process|
|regulation of anatomical structure morphogenesis|
|negative regulation of protein metabolic process|
|negative regulation of molecular function|
|positive regulation of cellular component organization|
|organonitrogen compound biosynthetic process|
|regulation of protein phosphorylation|
|ATP binding|
|regulation of phosphorylation|
|regulation of cell population proliferation|
|cellular nitrogen compound biosynthetic process|
|RNA metabolic process|
|cellular macromolecule biosynthetic process|
|small molecule metabolic process|
|macromolecule biosynthetic process|
|regulation of phosphate metabolic process|
|regulation of phosphorus metabolic process|
|regulation of protein modification process|
|positive regulation of gene expression|
|gene expression|
</modal>
\\

 === CRISPR Data ===
<button type='primary' size='small' modal='Compound_Hit'>Compound Hit</button>
<button type='primary' size='small' modal='Most_Correlated_Genes'>Most Correlated Genes in Chemogenomics</button>
<button type='primary' size='small' modal='Essential_Avana'>Tissues where Essential in the Avana Dataset (DepMap 20Q1)</button>

<modal id='Compound_Hit' size='lg' title='Compound Hit'>
^Screen^Score^
|[[:results:exp333|All-trans-Retinoic-Acid 8μM R07 exp333]]|-2.04|
|[[:results:exp406|Thalidomide 20μM R07 exp406]]|-2.02|
|[[:results:exp349|Cytochalasin-B 5μM R07 exp349]]|-2.01|
|[[:results:exp144|PFI-3 10μM R03 exp144]]|-1.94|
|[[:results:exp359|FK-506 30μM R07 exp359]]|-1.91|
|[[:results:exp342|Calcium Ionophore 0.4μM R07 exp342]]|-1.87|
|[[:results:exp391|Pomalidomide 20μM R07 exp391]]|-1.74|
|[[:results:exp409|THZ531 0.11μM R07 exp409]]|-1.74|
|[[:results:exp292|Menadione 5μM R06 exp292]]|-1.72|
|[[:results:exp7|Bortezomib 0.05μM R00 exp7]]|1.78|
|[[:results:exp102|Nifuroxazide 5μM R03 exp102]]|1.91|
|[[:results:exp98|BI-6727 0.04μM R03 exp98]]|1.96|
|[[:results:exp79|Q15 2.7μM R02 exp79]]|2.01|
|[[:results:exp459|Bleomycin 5μM R08 exp459]]|2.02|
</modal>

<modal id='Most_Correlated_Genes' size='lg' title='Most Correlated Genes in Chemogenomics'>
^Gene^Correlation^
|[[:human genes:r:rnmt|RNMT]]|0.488|
|[[:human genes:y:yars|YARS]]|0.458|
|[[:human genes:g:gtf3c2|GTF3C2]]|0.449|
|[[:human genes:g:gmppb|GMPPB]]|0.447|
|[[:human genes:h:hspd1|HSPD1]]|0.447|
|[[:human genes:t:thoc3|THOC3]]|0.446|
|[[:human genes:s:srp68|SRP68]]|0.443|
|[[:human genes:c:cct7|CCT7]]|0.443|
|[[:human genes:r:rptor|RPTOR]]|0.437|
|[[:human genes:n:nars|NARS]]|0.432|
|[[:human genes:h:hars|HARS]]|0.429|
|[[:human genes:t:tti2|TTI2]]|0.425|
|[[:human genes:t:tmem41b|TMEM41B]]|0.425|
|[[:human genes:e:eif4e|EIF4E]]|0.423|
|[[:human genes:d:dpagt1|DPAGT1]]|0.417|
|[[:human genes:m:med16|MED16]]|0.416|
|[[:human genes:c:ccdc101|CCDC101]]|0.414|
|[[:human genes:m:meaf6|MEAF6]]|0.414|
|[[:human genes:d:dhps|DHPS]]|0.412|
|[[:human genes:d:dicer1|DICER1]]|0.411|
|[[:human genes:s:slc35b1|SLC35B1]]|0.409|
|[[:human genes:c:csnk2b|CSNK2B]]|0.407|
|[[:human genes:z:znf259|ZNF259]]|0.406|
|[[:human genes:r:rtcb|RTCB]]|0.403|
|[[:human genes:n:nae1|NAE1]]|0.402|
|[[:human genes:m:mars|MARS]]|0.402|
|[[:human genes:g:gnb1l|GNB1L]]|0.401|
|[[:human genes:p:pam16|PAM16]]|0.401|
</modal>

<modal id='Essential_Avana' size='lg' title='Tissues where Essential in the Avana Dataset (DepMap 20Q1)'>
Global Fraction of Cell Lines Where Essential: 624/739
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|1/1|
|909776.0|1/1|
|bile duct|26/28|
|blood|25/28|
|bone|21/26|
|breast|27/33|
|central nervous system|51/56|
|cervix|3/4|
|colorectal|11/17|
|esophagus|9/13|
|fibroblast|1/1|
|gastric|11/16|
|kidney|19/21|
|liver|19/20|
|lung|66/75|
|lymphocyte|15/16|
|ovary|23/26|
|pancreas|21/24|
|peripheral nervous system|16/16|
|plasma cell|11/15|
|prostate|1/1|
|skin|18/24|
|soft tissue|9/9|
|thyroid|1/2|
|upper aerodigestive|15/22|
|urinary tract|23/29|
|uterus|4/5|
</modal>

== Essentiality in NALM6  ==
    * **<color #00a2e8>Essentiality Rank</color>**: 92
    * **<color #00a2e8>Expression level (log2 read counts)</color>**: 6.06 
<button type='primary' size='small' modal='Dist_expr'>Expression Distribution</button>
<modal id='Dist_expr' size='lg' title='WARS Expression in NALM6 Cells: 6.06'>
{{:chemogenomics:nalm6 dist.png?nolink |}}
</modal>